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Cadmium, a heavy metal and carcinogen, is an environmental and workplace 
contaminate. As a known endocrine disruptor, it can mimic the proliferative effects of estrogen 
and is classified as a metalloestrogen. While the proliferative effect of estrogen on cancerous cell 
growth has been well established, the effects of cadmium have not been fully examined. To 
determine if cadmium stimulates growth in two human ovarian adenocarcinoma cell lines, 
OVCAR3 and SKOV3, cells were treated for 48 hours with varying concentrations of cadmium, 
0.001 µM – 10 µM, and growth was measured using a cell proliferation assay. Both cell lines 
showed a peak in cellular proliferation at 0.1 µM, and cell death was induced at 10 µM. Further, 
cadmium was shown to activate phosphorylation of ERK1/2, a key protein involved in estrogen 
signaling. To determine if cadmium-induced phosphorylation of ERK1/2 uses a similar signaling 
pathway as estrogen, inhibitors were used to block two key proteins in the estrogen signaling 
pathway including the estrogen receptor (α and ß) and MEK. Following treatment with each 
inhibitor, cells were treated with cadmium for five minutes, and immunoblot analysis was used 
to measure the level of ERK1/2 phosphorylation. Preliminary results suggest the inhibition of 
MEK decreases ERK1/2 phosphorylation in SKOV3 and OVCAR3 cell lines. However, results 
demonstrate that inhibiting the estrogen receptors α and ß does not inhibit phosphorylation of 





Ovarian cancer is the most fatal gynecologic cancer and the fifth most fatal cancer in 
females, causing more death than breast cancer. Each year, over twenty thousand women are 
newly diagnosed with ovarian cancer, and fourteen thousand women will lose their lives to this 
silent killer.1 Unfortunately, due to lack of research and funding, ovarian cancers remain hard to 
diagnose and many are not found until they’ve reached stage III or IV, significantly decreasing 
chance of survival.1 In fact, the fatality rate of ovarian cancer continues to be 50% due to late-
stage diagnosis and commonality of recurrence after treatment.2, 3 While estrogen has been 
shown to play a key role in the proliferation of both breast and ovarian cancer, ovarian 
adenocarcinoma cells have failed to respond to anti-estrogen therapy in the same manner as 
breast cancer, leading to further questions of the pathway of endogenous and exogenous 
estrogens in ovarian cells.3 The purpose of this study is to provide more insight into the response 
and activation of cellular proliferation in ovarian adenocarcinoma cells due to cadmium, an 
exogenous contaminate able to mimic estrogenic effects.  
Ovarian Cancer 
 The American Cancer Society estimated 21,750 women in the United States would be 
diagnosed with ovarian cancer in the year of 2020.4 Of those women, it was estimated 13,940 
would die due to the cancer.4 Epidemiologically, rates are highest among white, non-Hispanic, 
post-menopausal women with diagnosis rates peaking between 50-70 years of age.5 A 46% 
survival rate continues to be a harsh reality many women diagnosed with ovarian cancer face, 
and most of these deaths could have been avoided had there been an effective method to screen 
for early-stage diagnosis.1, 5 It is the continued goal of researchers to better understand 
preventative strategies, risks, manifestation, screening, and treatment of ovarian cancer.  
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 The three main types of ovarian cancers are epithelial, germ cell, and sex-cord-stromal 
with epithelial ovarian cancer (EOC) making up about 95% of all ovarian cancer types.1 EOC 
can be further divided into four subtypes, serous, endometrioid, mucinous, and clear cell, with 
serous EOC being further divided into high-grade serous carcinomas (HGSC) and low-grade 
serous carcinomas.1 HGSC’s account for 90% of all ovarian cancer tumors, and there is only a 
30% survival rate for women with this subtype.1 These statistics have remained relatively 
unchanged over the past thirty years, indicating a huge gap in scientific knowledge.1  
 Originally, it was believed all EOC’s originated in the outer epithelium layer of the 
ovaries, but it was later found there are three points of origin.1 Malignant growths can start in the 
epithelium of the ovaries, fallopian tubes, or other sites in the pelvis, making it hard to pinpoint 
the genetic and environmental triggers for EOC.1 These malignant growths then proceed in a 
manner like other cancers, staying benign or metastasizing to other areas of the body. It is 
metastasized tumors which present such a concern since they become widespread and almost 
untreatable.  
 Researchers have identified a wide variety of risks leading to EOC. Most likely, it is a 
combination of several of these risk factors which lead to the manifestation of the disease. 
Firstly, several genes have been identified to increase the likelihood of ovarian cancer.1, 5 Most 
notable is the BRCA mutation often associated with breast cancer. The presence of BRCA 1 is 
associated with a 40-50% of EOC development by the age of seventy while BRCA 2 accounts 
for a 20% risk increase.5  When a woman with a BRCA mutation develops EOC, the tumor is 
referred to as Type II and is highly associated with fatal outcomes.1, 5 
 When a tumor cannot be linked to a genetic mutation, it is referred to as a Type 1 tumor 
and is theorized to be caused by increased inflammation due to the repeated breakdown and 
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repair of the epithelial layer.5 The age women begin menstruating, when they reach menopause, 
and the number of pregnancies along with duration of breastfeeding all have been shown to 
factor into the development of EOC.1, 5, 6 The American Cancer Society attributes increased 
number of ovulation cycles to an increase in risk for EOC. Unfortunately, the average age 
women begin menstruating has decreased from 16 years to 12.5 years meaning their ovulation 
cycles, on average, are four years longer than they used to be.5 Anything which halts ovulation, 
such as oral contraceptives, pregnancy, and breastfeeding, are associated with decreasing the risk 
of ovarian cancer due to decreased stress on reproductive systems related to menstruation.5 
However, it is important to note these are not preventative strategies for ovarian cancer as the use 
of oral contraceptives, pregnancy, and breast-feeding are lifestyle burdens not every woman 
wishes to undergo. 
 The lack of consistent and accurate screening for ovarian cancer remains a large factor 
contributing to its mortality rate. Late-stage EOC, which includes both stage III and IV cancer, is 
difficult to treat and often recurs after initial treatment.1, 6  Further, the symptoms associated with 
ovarian cancer are non-specific and occur commonly in women for a wide variety of non-cancer 
related issues such as abdominal bloating, abdominal pain, nausea, frequent urination, change in 
bowel movements, back pain, loss of weight, and fatigue.6 In the past, health care professionals 
screened for the cancer antigen 125 (CA125) as a tumor marker for ovarian cancer, but it has 
recently been shown that this marker lacks specificity and sensitivity as it was not elevated in 
50% of patients during early stage EOC.1 Since the CA125 screen has been proven to be 
unreliable, it is increasingly harder to make an early diagnosis. Currently, health care 
professionals rely on a combination of knowing a patient’s genetic risks, their symptoms, and a 
transvaginal sonography scanning for pelvic masses to determine if there are any masses which 
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require biopsy.1 Once a mass has been identified, only a biopsy can confirm the diagnosis of 
ovarian cancer. Unfortunately, even this procedure comes with risks as the core-needle biopsy 
used to collect tissue can result in abdominal wall metastasis.1 Most biopsies will result in a 
diagnosis of stage III EOC. 
 The most common treatment for ovarian cancer involves a debulking surgery followed by 
chemotherapy.1 With debulking surgery, surgeons remove the majority of the tumor to increase 
the effectiveness of chemotherapy since there will be less malignant cells present. With advanced 
cell EOC, chemotherapy begins with the administration of carboplatin and paclitaxel over six to 
eight therapeutic cycles.1, 6 Despite these treatment steps, remission is not ensured, and patients 
who do go into remission have up to a 95% rate of recurrence in late-stage ovarian cancers.1 
Understanding how this deadly cancer functions is vital to create better screening and treatment 
for the women who develop this disease.  
Estrogen  
 Estrogens are hormones vital to the development of sexual and reproductive functions in 
both males and females. In females, androstenedione is produced from cholesterol in the theca 
cells adjacent to granulosa cells in the ovaries.7 This androgen is then transported to granulosa 
cells with high concentrations of the enzyme aromatase responsible for converting 
androstenedione to estrogen.7 From there, estrogen is converted to its most potent biologically 
active form, estradiol, and can then circulate in the blood stream to induce effects on various 
tissues.7 Endogenous estrogen production is highest in pre-menopausal women and has a wide 
variety of regulatory functions within the body, with the most important being breast, mammary 
gland, and ovary development and ovulation maintenance.7-9 However, elevated levels of 
estrogen in post-menopausal women have been associated with the development of breast and 
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ovarian cancer.8 Due to this, it is normal and desirable for estrogen production to decrease in age, 
especially after a woman reaches menopause.  
 The interaction of estradiol with estrogen receptors (ERs) is responsible for cellular 
changes associated with estrogen, including cellular proliferation. Estrogen receptors, such as 
ER-α and ER-β, are part of a steroid receptor subfamily of transcription factors which play a role 
in breast, uterine, and ovarian cancer.10 Previously, the nuclear membrane was the accepted 
location of ERs. In recent years, the presence of plasma membrane estrogen receptors has opened 
up a wider avenue for estrogen action.11  
Each ER is functionally distinct, and recent research has proposed ER-β opposes the 
action of ER-α.9, 12 In fact, the ratio of ER-α to ER-β has been suggested as a potential marker for 
carcinogenesis in several estrogen-sensitive cancers.3, 13 Within ovarian cancer, 67% percent of 
patients are ER positive and have a higher ratio of ER-α to ER-β, suggesting increased levels of 
ER-α are pro-tumorigenic.3 Furthermore, a decrease or lack of ER-β in estrogen-sensitive cancer 
has led researchers to investigate the anti-proliferative effects of ER-β, suggesting the binding of 
estradiol to ER-β can inhibit pathways activated by ER-α.3, 12 Furthermore, tumors can decrease 
the expression of ER-β but the mechanism by which they achieve this remains largely 
unknown.12 Some have even begun to speculate if ER-β can be used in tandem with estrogen 
antagonists for the treatment of estrogen-sensitive cancers.12 
 Nuclear estrogen receptors are intracellular receptors with a dimerized structure of 
cysteine residues regulated by a zinc binding domain.14, 15 When activated by estrogen or an 
estrogen-like-chemical, the ER protein binds to DNA at specific nucleotide sequences termed 
oestrogen response elements.15 ER-α and ER-β were found to be evolutionarily conserved 
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structurally with a highly conserved DNA binding domain, COOH-terminal ligand binding 
domain, and variable NH2-terminal domain.9  
With the recent discovery of membrane-bound ER, the process of estrogen signaling in 
ovarian cells has become more complicated. Membrane-bound ERs function in a different 
manner and have been shown to interact with a G-protein coupled estrogen receptor 1 (GPER1) 
to activate a protein kinase cascade eventually leading to DNA regulation (Figure  1).3, 11 The 
crosstalk between ERα and GPER1 has become a large point of study in ovarian 




Figure 1: Estrogen signaling pathway kinase cascade through membrane-bound ER 
activation. ICI 182,780 and PD98059 are shown by the step which they inhibit. Figure 
adapted from Levin et al. (2008).11 
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Under normal conditions, estradiol binds to membrane-bound ER-α located in lipid 
domain rafts within the cellular membrane and initiates a cascade of events that results in 
increased cellular proliferation.16 Upon estrogen binding, ER-α interacts with transmembrane 
growth factors, including the epidermal growth factor receptor (EGFR). EGFR, not shown in 
Figure 1, then activates Src kinase which in turn activates MEK. MEK activation induces the 
phosphorylation of ERK1/2 which then phosphorylates a number of signaling proteins that 
induce cellular proliferation.16, 17 It is thought EGFR, Src and MEK also play important pro-
tumorigenic roles in cancerous cell growths, making them possible key players in estrogen and 
estrogen-like interaction and activation of cellular proliferation in ovarian cancer.17-19 
 One common method used to treat estrogen-sensitive cancers is the use of anti-estrogens 
to block the proliferative effect of ER-α. In breast cancer, the anti-estrogen tamoxifen is the first 
line of treatment for hormone dependent, ER+ breast cancer.8, 9 Due to its success, it was 
proposed as a therapy in ER+ ovarian cancers. However, EOC has shown a large resistance to 
anti-estrogen treatment due to estrogen resistance in these cell lines.3, 12 One emerging theory 
suggests that because tamoxifen blocks both ER-α and ER-β, ER-β is unable to halt cellular 
proliferation.12 Furthermore, estrogen signaling pathways are able to interact with several 
oncogenic pathways, promoting cellular proliferation even when the effects of estrogen are 
blocked by the ER-antagonist tamoxifen.3 Crosstalk between estrogen signaling pathways most 
likely results in the lack of success seen in anti-estrogen treatment for EOC. The speculation 
behind anti-estrogen treatment resistance in EOC demonstrates the complexity of hormone 





Endocrine Disruptors and Metalloestrogens 
 Along with endogenous hormones produced by the body, there are a wide variety of 
natural and synthetic compounds that can interact with hormonal function and are referred to as 
endocrine disruptors (EDs).20 These endocrine disruptors can interfere or react with receptor 
binding and the metabolism of hormones to increase or decrease the effects of hormones within 
the body.20, 21 Many are familiar with the endocrine disruptor DDT which was once used as a 
common pesticide before it was determined to have hazardous effects on the environment and 
humans. It was classified as an ED due to its ability to interfere with several hormonal functions, 
including estrogen and androgen action.20 Since then, significantly more EDs have been 
discovered and classified. 
 The issue with endocrine disruptors is their ability to interfere with the natural 
homeostatic processes within the body that rely on hormonal signaling.20 When exposure occurs 
early in life, EDs can significantly impact development and fertility of many organisms, 
including humans.20, 21 Due to this, it is important to identify EDs and limit their release into the 
environment to decrease exposure to developing organisms. While DDT has been banned due to 
its adverse effects as an ED, there remain many common pollutants in this category.20 
 Many are familiar with bis-phenol-a (BPA) as a stabilizing agent commonly used in 
plastics. Over recent years, concern was raised over the estrogenic effects of BPA on the body, 
especially since exposure rates from plastic bottles was so high.22 Levy et al. (2004) discovered 
BPA can interact with ER as an exogenous estrogen and induce feminizing effects on tadpoles, a 
key study in raising public awareness to the dangers of EDs and BPA.22 In this study, it was 
shown that under normal conditions, the ratio of male to female tadpoles is 50:50.22 When 
exposed to the environmental contaminant of BPA, the percentage of females rose as high as 
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80%, demonstrating the estrogenic effects of BPA could determine the sex of tadpoles at the 
larval stage.22 This has serious implications in ruining the balance of natural environments by 
altering the natural ratio of male to female frogs. Furthermore, it is possible BPA also has 
adverse effects on fertility which were not examined in this study. 
 While it is hard to determine exposure events due to the wide pollution of EDs in the 
environment, Rattan et al. (2017) studied how exposure to EDs could affect female fertility in 
adults. It is known that reproductive functions in females are highly dependent on a balance of 
hormones, mainly estrogen. Any increase in exogenous hormone exposure is likely to cause 
adverse effects, including increased risk for ovarian cancer.21, 23 Identifying endocrine disruptors 
and limiting exposure is highly important for the health of females. 
Recent studies have demonstrated heavy metals can have estrogenic effects on the body 
and that this action may occur through a nonspecific interaction with the estrogen receptor. Since 
ERs have a large ligand binding cavity, many EDs are able to interact and increase negative 
hyper-estrogenic effects in individuals exposed to contaminants.9  This recently defined group of 
heavy metal EDs, termed metalloestrogens, are naturally occurring chemicals which mimic or 
interfere with the actions of estrogen within the body.15  It is also known heavy metals are 
common carcinogens. These carcinogens with estrogen-like activity may increase carcinoma 
growth by stimulating estrogen receptor pathways responsible for increasing cell proliferation.15 
How and which pathways metalloestrogens interact with are largely still under investigation in 
several types of adenocarcinomas, including EOC.  
Over the years, heavy metal environmental contamination has increased due to 
urbanization and industrial processes.24 Cadmium (Cd) remains an environmental contaminant of 
concern due to the effect it has on the body; causing oxidative stress, DNA damage, and 
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inhibition of DNA repair mechanisms.18 Combined, these effects can increase the risk of cancer 
in individuals exposed to Cd. This exposure can occur through environmental contamination of 
water, air, food, and plants, occupational exposure, or through an individual’s use of cigarettes.2 
Cd persists in soft tissues for 15-20 years and has even been linked to increased proliferation in 
lung cancers.2, 18 The mechanism of cadmium action that results in cellular proliferation has 
earned it a spot in the emerging class of metalloestrogens. 
 Originally, studies focused on the cytotoxic effects of cadmium and other heavy metals 
demonstrated exposure increased the susceptibility of cancer manifestation due to the inhibition 
of several key cellular functions.25 However, a person is more likely to be exposed to chronic 
low levels of Cd than singularly being exposed to high concentrations. In 2006, Brama et al. 
showed that exposure of breast cancer cells to 10 µM CdCl2 induced cellular proliferation 
through the interaction of Cd with ER-α.26 This research provided evidence that metalloestrogens 
could mimic the effects of estradiol in low concentrations and with an estrogen dependent 
cancer, such as breast cancer, cellular proliferation of cancerous cells could be increased in 
women chronically exposed to Cd. 
 Zang et al. (2009) provided further evidence for the interaction of Cd with ER and the 
activation of ERK1/2.27 After ten minutes of 1 µM Cd exposure, breast cancer cells showed 
increased phosphorylation of ERK1/2.27 Through treatment with the ER inhibitor ICI 182,780, 
cadmium-induced phosphorylation of ERK1/2 was inhibited, suggesting an ER dependent 
pathway of activation.27 Other studies, discussed below, have also shown estrogen dependent 
cancers increase in proliferation upon Cd exposure and support an ER dependent mechanism. 
 In 2016, Huff et al. reported their findings on the effect of Cd on several lung 
adenocarcinoma cell lines. In these studies, it was found that in cell lines derived from female 
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patients, Cd induced cellular proliferation and caused increased levels of phosphorylated 
ERK1/2, both of which were inhibited when the estrogen receptors were blocked by the addition 
of an estrogen receptor antagonist, ICI 182,780.18 Through inhibitor studies, it was found that 
Src, epidermal growth factor (EGFR) and GPER were necessary for cadmium-induced ERK1/2 
phosphorylation.18 This study suggests Cd interacts with G-protein coupled ERs in female lung 
adenocarcinomas to stimulate cellular proliferation through the activation of the ERK1/2 
pathway.  
Purpose of Study 
 Based on previous studies, cadmium has demonstrated estrogen-like activity in a number 
of different tissues, inducing cellular proliferation in an ER-dependent manner.15 It seems likely 
other estrogen-sensitive tissues, including ovarian tissue, might also respond to Cd in a similar 
way. Using two different ovarian cell lines, OVCAR3 and SKOV3, preliminary results in the 
Huff lab suggested Cd may slightly increase cellular proliferation in OVCAR3 while the SKOV3 
cell line does not. Studies conducted by Pujol et al. (1998) have shown that SKOV3 cells have a 
deleterious mutation in ER-α, truncating the resulting protein and rendering it unable to bind 
estrogen.13 This difference in a functional ER-α might explain the differential response to Cd that 
has been observed.   
 Furthermore, Biochemistry and Molecular Biology student Kira Steinke showed that 0.1 
µM of Cd activated ERK1/2 in both OVCAR3 and SKOV3 cell lines within 10 minutes of 
treatment. These results show there is ERK1/2 phosphorylation occurring in OVCAR3 and 
SKOV3 upon treatment with Cd. However, it has not been confirmed this phosphorylation 
induced by Cd works in an ER dependent manner. It could be possible the phosphorylation in 
OVCAR3 occurs through ERs while another pathway is responsible for the phosphorylation in 
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SKOV3 due to the mutation in ER-α. Pathways of Cd interaction in ovarian cancer have yet to be 
identified. 
The purpose of this study is to first extend the proliferation studies to determine if these 
two cell lines demonstrate differential responses to Cd and then study ERK1/2 phosphorylation 
after inhibition of ERs and MEK. The research should provide insight into the signaling 
pathways that are activated by Cd to cause a cellular cascade in OVCAR3 and SKOV3 ovarian 
adenocarcinoma cell lines.  
 
METHODS 
Cellular Proliferation Assays 
Two human ovarian adenocarcinoma cell lines, OVCAR3 and SKOV3, were obtained from 
ATCC (Manassas, VA) and grown following manufacturer’s directions. To conduct treatments 
with cadmium and estradiol, cells were plated at 5,000 cells per well in a 96-well plate. For 
SKOV3, cells were plated in 200 µL of McCoy’s 5a containing 10%(v/v) FBS (ATCC) and 1% 
penicillin/streptomycin (Thermo-Fisher, Waltham, MA) growth media. For OVCAR3, cells were 
plated in 200 µL of RPMI 1640 containing 10%(v/v) FBS, 0.01 mg/mL bovine insulin (Sigma-
Aldrich, St. Louis, MO) and 1% penicillin/streptomycin (ThermoFisher). Cells were allowed to 
grow for 24 hours before the growth media was changed to the appropriate experimental media 
lacking hormones and supplemented with 10% charcoal-stripped fetal bovine serum. After 
another 24 hours, cells were treated in quadruplicate with varying cadmium (CdCl2) 
concentrations ranging from 0.001 µM to 10 µM or estradiol concentrations ranging from 0.001 
µM to 0.1 µM. No treatment was used as the control for the cadmium studies while 1% ethanol 
was used as the control for the estradiol studies. Cells were treated for 48 hours, and cellular 
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proliferation was measured using the Promega CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (Madison, Wisconsin) following manufacturer’s instructions. A BioRad 680 
plate reader (Hercules, CA) was used to determine the absorbance readings at 490 nm. These 
experiments were repeated 4-5 times for each cell line. 
 
Inhibitor Studies 
OVCAR3 and SKOV3 cell lines were grown at 400,000 cells in 3 mL of respective growth 
media on a 60 cm3 petri dish for 48 hours. The media was then replaced with 3 mL of media 
lacking hormones and containing charcoal-stripped fetal bovine serum for 48 hours. To inhibit 
the estrogen receptors alpha and beta, cells were pretreated with 10 µM ICI 182,780 dissolved in 
DMSO from Tocris Bioscience (Minneapolis, MN) for one hour. For the inhibition of MEK, 
cells were pretreated with 50 µM PD98059 (Cell Signaling Technology, Danvers, MA) dissolved 
in DMSO for one hour. Cells were then treated with 0.1 µM CdCl2 for 10 minutes, and cell 
lysates were prepared. To prepare whole cell lysates, media was removed, and cells were washed 
with ice-cold phosphate buffered saline two times. Cells were then treated with 60 µL of ice-cold 
cell lysate buffer prepared with 1 mL RIPA buffer (Sigma), 1 µL Phosphatase Inhibitor Cocktail 
2 (Sigma), 1 µL of Phosphatase Inhibitor Cocktail 3 (Sigma), 1 µL Protease Inhibitor Cocktail 
(Sigma), and 10 µL of 100 mM PMSF. Cells were scraped from the petri dish on ice and 
collected in microcentrifuge tubes. Each lysate was sonicated for 1 second two times using a 
Microson™ ultrasonic cell disruptor (Barcelona, Spain) before being centrifuged for 10 minutes 





SDS Gel Electrophoresis and Immunoblot Analysis 
Proteins (25 µg) were separated on a 4-20% polyacrylamide SDS gel at 300 V for 15 minutes 
and transferred to a nitrocellulose membrane for immunoblot analysis. The blot was blocked in 
5% milk in TTBS (20 mM Tris pH 7.4, 140 mM NaCl, 0.1% Tween-20) for one hour at room 
temperature. The blot was washed with TTBS 1x15 minutes and 3x5 minutes and then incubated 
with a primary polyclonal antibody at a 1/1000 dilution raised to phospho-ERK1/2 from Cell 
Signaling Technology overnight with shaking at 4°C. Following washes as described above, the 
blot was treated with a 1/1000 dilution of goat anti-rabbit conjugated with horseradish 
peroxidase polyclonal antibody from ThermoFisher. After washing, the blot was exposed to a 1:1 
dilution of the ECL reagents from BioRad for five minutes before being imaged on a BioRad 
Chemidoc system. The membrane was then stripped for ten minutes using Stripping Buffer from 
Thermo Scientific and re-probed with a 1/1000 dilution of antibody raised to total ERK1/2 from 
Cell Signaling Technology. The proteins were exposed to ECL reagents as previously described 
and imaged once more. The images were analyzed by densitometry using Unscan-it software 




 The ovarian adenocarcinoma cell lines OVCAR3 and SKOV3 were used to determine the 
proliferative effect of Cd and estradiol on EOC. Both cell lines are epithelial in origin and were 
cultured from post-menopausal females, making them an ideal representative for ovarian cancer 
response in these studies. As previously stated, there is a difference in ER-α expression between 
the two cells lines, with SKOV3 containing a 32 bp mutation hypothesized to be responsible for 
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estrogen-insensitivity in this cell line. Cells were treated for 48 hours with Cd concentrations 
ranging from 0.001 µM to 10 µM, and cellular proliferation was determined using Promega 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay. Experiments were repeated in 
quadruplicate and averaged for six trials. As shown in Figure 2A, OVCAR3 demonstrated slight, 
but insignificant, cellular proliferation when treated with nanomolar concentrations of Cd when 
compared to the control. This proliferation peaked with 0.1 µM Cd treatment at 106% ± 4% 
S.E.M of the control. When treated with 10 µM Cd, OVCAR3 cells experienced significant cell 
death with only 61% ± 8.8% S.E.M proliferation compared to the control. This suggests there is 
a fairly significant line between chronic low doses of Cd which may induce proliferation and 
doses which induce death.   
SKOV3 also demonstrated slight but insignificant cellular proliferation when treated with 
low concentrations of Cd, as demonstrated in Figure 2B. Cellular proliferation peaked with a 
treatment of 0.01 µM Cd at 105% ± 2.9% S.E.M of the control. As with OVCAR3, treatment of 
SKOV3 with 10 µM Cd induced cell death with proliferation only 87% ± 4.5% S.E.M. of the 
Figure 2: Treatment with Cd does not significantly affect cellular proliferation in (A) 
OVCAR3 and (B) SKOV3 cell lines. Cells were treated with 0.001 µM Cd to 10 µM Cd. 
Results are reported as relative to untreated control. 
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control. What was unexpected was treatment with 0.001 µM Cd consistently showed a decrease 
in cellular growth as compared to the control (91% ± 1% S.E.M proliferation). 
Cells were treated for 48 hours with estradiol (E2) concentrations ranging from 0.001 µM 
to 0.1 µM, and cellular proliferation was determined using Promega CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay. Experiments were repeated in quadruplicate and averaged for 
six trials. As shown in Figure 3A, OVCAR3 showed no significant increase in proliferation when 
compared with the control, even though these cells are derived from estrogen-responsive tissues. 
This data suggests estrogen does not have a proliferative role in OVCAR3 cells. 
More interestingly, SKOV3 responded differently to estradiol treatment as shown in 
Figure 3B. Treatment with 0.001 µM and 0.01 µM estradiol was comparable to the control of 
ETOH, while treatment with 0.1 µM showed decreased cellular proliferation of 88% ± 5% 
S.E.M of the control. Perhaps, because SKOV3 does not contain a functional ER-α, estradiol is 




Figure 3: Treatment with Estradiol (E2) does not significantly affect cellular 
proliferation in (A) OVCAR3 and (B) SKOV3 cell lines. Cells were treated with 0.001 µM 




 Previous studies performed by Kira Steinke in the Huff lab showed that ERK1/2 was 
activated by 0.1 µM Cd within 10 minutes of treatment (unpublished data). To determine if Cd-
induced activation of ERK1/2 involves membrane-bound ERs, SKOV3 and OVCAR3 cells were 
treated with the ER antagonist, ICI 182,780, one hour before treating the cells with Cd for ten 
minutes. As shown in Figure 4, Cd increased ERK1/2 phosphorylation alone in both SKOV3 and 
OVCAR3 cells.  When the ER antagonist was added, there was a 50% increase in activation in 
OVCAR3 cells. In contrast, SKOV3 cells showed a 23% decrease in ERK1/2 phosphorylation 
Figure 4: Inhibition of ER with ICI 182,780 does not inhibit Cd-induced ERK1/2 
phosphorylation in OVCAR3 but has some affect in SKOV3. (A&B) Results of 
immunoblots for OVCAR3 and SKOV3, respectively. (C&D) Quantitative analysis of relative 
P-ERK1/2 performed using Unscan-it software. Cells were treated with 10 µM ICI 182,780 
(ICI) for one hour before a ten-minute treatment with 0.1 µM Cd. Results are reported as % P-
ERK/Total ERK relative to the untreated control and averaged for three trials. 
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when first treated with the ER antagonist.  These results suggest ICI inhibits some of the Cd-
induced ERK1/2 phosphorylation in SKOV3 cells but not in OVCAR3 cells. 
 Next, mitogen-activated protein kinase (MEK) was inhibited using PD98059 to confirm 
the activation of ERK1/2 upon Cd treatment. While it is likely that the ERs are not involved in 
the activation, inhibiting the signaling protein before ERK1/2 phosphorylation will begin to 
confirm the steps leading to phosphorylation. The results are shown in Figure 5. Once again, 
ERK1/2 phosphorylation was increased by Cd alone in both SKOV3 and OVCAR3 cells. When 
the MEK antagonist was added, there was a 131% decrease in activation in OVCAR3 cells and a 
238% decrease in activation in SKOV3 cells. These results suggest MEK plays a key role in Cd-
induced ERK1/2 phosphorylation.  
Figure 5: Inhibition of MEK with PD98059 inhibits Cd-induced ERK1/2 
phosphorylation in OVCAR3 and SKOV3 cell lines. (A&B) Results of immunoblots for 
OVCAR3 and SKOV3, respectively. (C&D) Quantitative analysis of relative P-ERK1/2 
performed using Unscan-it software. Cells were treated with 50 µM PD98059 (PD9) for one 
hour before a ten-minute treatment with 0.1 µM Cd. Results were reported as % P-ERK/Total 




 Chronic exposure to low doses of the environmental contaminant cadmium (Cd) has been 
linked to cellular proliferation in breast, lung and ovarian cancer.2, 18, 26 The pathway of Cd action 
has been well defined in breast and lung cancer and has been shown to interact with ERs leading 
to phosphorylation of ERK1/2, DNA modification, and cellular proliferation. However, it 
remains unclear if this same pathway is activated in the estrogen-sensitive ovarian cancer. These 
results demonstrate that phosphorylation of ERK1/2 occurs through a MEK dependent pathway 
upon low doses of Cd exposure, but they do not confirm an ER dependent mechanism of action. 
These results also discovered low doses of Cd exposure did not significantly increase cellular 
proliferation, demonstrating ovarian adenocarcinomas behave differently from breast and lung 
adenocarcinomas.  
 The working hypothesis of this study proposed that Cd would induce proliferation in 
ovarian cells and that this growth would occur through an ER-dependent mechanism. The 
functionality of ER-α mRNA transcripts in OVCAR3 was confirmed by Lau et al. (1999), and 
other research shows increased ratios of ER-α to ER-β in OVCAR3 cells compared to human 
epithelial surface epithelium cells (HOSE), which are non-cancerous ovarian cells.10, 13, 28 Yet in 
these studies, OVCAR3 cells showed only slight increase in proliferation compared to the 
control when treated with 0.1 µM Cd for 48 hours, but this difference was not significant. Since 
OVCAR3 cells also did not respond to estradiol treatments in this study, it is likely that estrogen 
signaling does not play a significant role in the proliferation of OVCAR3. 
 Steinke’s data (unpublished) does show increased levels of relative P-ERK/Total ERK in 
OVCAR3 cells treated with 0.1 µM Cd which persist from 5 to 15-minutes and peaks at the 10-
minute mark. This confirms low doses of Cd are activating phosphorylation of ERK1/2, but it 
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remains unclear what role this is playing on a cellular level since there is no significant increase 
in cellular proliferation. In this study, inhibition of MEK significantly decreased Cd-induced 
ERK1/2 phosphorylation in OVCAR3 cells, showing it is a necessary signaling protein involved 
in the pathway. Further testing focused on the inhibition of suspected key players in the 
phosphorylation of ERK1/2 by Cd is needed to determine the pathway of its action in OVCAR3 
cells. 
The results of this study demonstrated that inhibition of ERs using the ER antagonist, ICI 
182,780 (ICI), did not affect the activation of P-ERK1/2 in OVCAR3 cells. These results further 
support that Cd does not act in an ER-dependent manner in OVCAR3 cells to induce 
phosphorylation of ERK1/2. These results are consistent with previously published data that 
demonstrated ovarian cells do not respond to anti-estrogen treatments and provides further 
support that Cd does not act in an ER-dependent manner in this cell line.3 Since ERs are not 
playing a significant role in the phosphorylation of ERK1/2 by Cd, this means there are other 
proteins playing a role in MEK activation in the OVCAR3 cell line.  
When cells were treated with the ER antagonist alone, there was an increase in relative P-
ERK/Total ERK compared to the control in both cell lines. Since ICI is non-selective and will 
block both ER-α and ER-β, this may account for the increase that was observed in both cell lines. 
Lazennec (2005) has proposed ER-β could function as a tumor suppressor protein since its levels 
are downregulated in ovarian carcinogenesis and ER-α is upregulated.12 Furthermore, it was 
shown that the restoration of ER-β decreased cellular proliferation and increased 
adenocarcinoma apoptosis.12 Since ER-β was inhibited along with ER-α upon ICI treatment, it is 
possible this removed the inhibitory action of ER-β and allowed increased signaling cascades 
from other pathways to be activated leading to phosphorylation of ERK1/2. More research needs 
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to be conducted to determine the effect of ICI treatment alone on the cellular proliferation of 
OVCAR3 cells to determine if blocking ER activity may activate, rather than inhibit cell growth.  
 SKOV3 cells responded in a different manner than OVCAR3, showing a slight increase 
when treated with 0.01 µM Cd for 48 hours compared to the control, but it was also not 
significant. Lau et al. (1999) discovered a 32 base-pair deletion in SKOV3 ER-α transcripts, 
suggesting that this resulted in loss of ER-α function rendering these cells estrogen-insensitive.28 
This could account for the lack of response seen in SKOV3 cells when treated with the 
metalloestrogen Cd. It also accounts for the lack of growth seen in SKOV3 cells treated with 
estradiol. If Cd is affecting SKOV3 cells, it is not causing an increase in cellular growth within 
the two days of treatment performed in this study. 
 Even though Cd does not appear to induce proliferation in SKOV3 cells, low 
concentrations of Cd significantly increase phosphorylation in ERK1/2 within minutes of 
treatment. Steinke (unpublished results) demonstrated there was a significant increase in relative 
P-ERK/Total ERK after 5 minutes of 0.1 µM Cd treatment in SKOV3 cells and this increase 
persisted until the 10-minute mark. Interestingly, at the 15-minute mark Steinke’s data showed a 
decrease in relative P-ERK/Total ERK compared to the control. Perhaps there are pathways at 
work within SKOV3 cells to counteract the ERK1/2 activation induced by Cd. This could also 
account for the lack of results seen in cellular proliferation studies.  
 Treatment of SKOV3 cells with ICI did decrease ERK1/2 phosphorylation caused by Cd. 
It is interesting this cell line responded differently to ICI inhibition of ERs than OVCAR3 
considering the SKOV3 cell line does not have a functional ER-α. Once again, there was an 
increase in ERK1/2 phosphorylation when SKOV3 cells were treated with the estrogen receptor 
inhibitor alone, and this elevated level was also maintained in the cadmium and ICI treatment 
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group. Even though treatment with an estrogen receptor inhibitor reduced the level of Cd-
induced phosphorylation of ERK1/2, it is likely estrogen receptors do not play a significant role 
in SKOV3 cells treated with cadmium because levels were not returned to the control. However, 
just like OVCAR3 cells, inhibition of MEK in SKOV3 cells treated with Cd resulted in a 
significant decrease in phosphorylated ERK1/2. This demonstrates, once again, Cd is inducing 
the activation of MEK and this activation is necessary for ERK1/2 phosphorylation.  
 In 2019, Ataei et al. published their work on the role of cadmium in ovarian 
adenocarcinoma. However, the work published in this paper did not align with the preliminary 
work conducted by the Huff lab. Ataei et al. (2019) found low concentrations of Cd, 0.1 µM or 
less, resulted in significant increases in cellular proliferation.2 Even when replicating cellular 
proliferation methods of Ataei et al. (2019), the results of this research never confirmed low 
doses of Cd could induce significant cellular proliferation. Furthermore, Ataei et al. (2019) 
showed treatment with ICI was able to inhibit the cellular proliferation induced by low 
concentrations of Cd, 0.001 µM to 0.1 µM.2 This data lead to the hypothesis ICI would inhibit 
the phosphorylation of ERK1/2 in SKOV3 and OVCAR3 cell lines, but again this was not 
confirmed in this study. Even though the same cell lines are being utilized, it is possible the 
discrepancy in results could be due to different lab environments. Overall, these differences 
show how difficult it is to understand ovarian adenocarcinomas and why they remain such a 
troubling disease.  
 To further understand how Cd activates ERK1/2 in these cell lines, future studies will be 
designed to examine the inhibition of other key proteins suspected to be involved in Cd-induced 
signaling. The non-receptor protein-tyrosine kinase, Src, has been studied for years due to its 
upregulation in a variety of human cancers and its role as a protooncogene.17 Src plays a key role 
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in cellular proliferation and its increased expression in breast cancer has been linked to another 
key protein, epidermal growth factor receptor (EGFR).17 While it is known to be overexpressed 
in ovarian cancers, it remains unclear its role in the production of ovarian neoplasms.17 By 
inhibiting Src in SKOV3 and OVCAR3 cells with PP2, it can be determined if it plays a role in 
the phosphorylation of ERK1/2 by Cd. 
 Another key protein to study as its possible involvement in Cd-induced phosphorylation 
is EGFR. EGFR is part of a tyrosine kinase receptor family, plays a role in cellular proliferation 
and is often seen to be overexpressed in human cancers.19 If Cd is activating MEK through the 
Figure 6: Representation of ERK1/2 phosphorylation due to binding of Cd to receptor 
tyrosine kinases in uterine cells. * marks the possible path of Cd action in ovarian cancer 
cells by binding to EGFR, activating MEK, and phosphorylating ERK1/2. Adapted from Gao 
et al. (2015).29 
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involvement of Src, it is most likely doing so through EGFR. To determine the role of this 
protein in the pathway of Cd-induced ERK1/2 phosphorylation, SKOV3 and OVCAR3 cells 
could be pretreated with the EGFR inhibitor AG1478. Identifying how these cellular signaling 
proteins work together with Cd to induce phosphorylation of ERK1/2 would aid in the 
understanding of Cd effects on ovarian adenocarcinomas.  
In 2015, Gao et al. published their results on the effect of Cd on uterine cells, another 
estrogen-sensitive tissue. Cd was shown to induce significant proliferation in uterine cells, and it 
was found classical ER pathways did not induce ERK1/2 phosphorylation.29 Instead, their results 
showed  inhibition of EGFR and MEK significantly reduced ERK1/2 phosphorylation induced 
by Cd.29 Considering the similar location of uterine and ovarian cells, it is possible ovarian cells 
follow similar pathways of ERK1/2 phosphorylation. Figure 6, adapted from Gao et al. (2015), 
demonstrates the alternate pathway of Cd action in uterine cells, which could be present in 
ovarian cells. Further research would help determine the action of receptor tyrosine kinases in 
Cd-induced ERK1/2 phosphorylation in ovarian cancer cells.  
The results of this research contribute to the ever-growing knowledge of Cd and ovarian 
cancer. Due to its carcinogenic effects and ability to persist in soft tissues for decades, Cd will 
remain an environmental contaminant of concern. Even if it is not acting as a metalloestrogen in 
ovarian adenocarcinoma cell lines, it is still important to determine its mechanism of action to 
understand the full effect of low dose Cd exposure. Furthermore, increased understanding of 
cellular pathways within ovarian cancer can help guide research regarding early-stage diagnosis 
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